Until the advent of corticosteroids and colectomy, nearly a third of inpatients with ulcerative colitis died of their disease. Even with effective treatments available, challenges remain in the medical and surgical management of these patients.
Current treatments for hepatitis C virus (HCV) are quite effective, with a cure rate inching toward 100 percent. However, there are certain subpopulations that fail direct-acting antiviral (DAA) therapy and others who have yet to be diagnosed — up to 50 percent of people with the virus, according to some estimates.
While the need for advanced endoscopic training programs is expected to grow, various issues are yet to be resolved, such as accreditation, assessment and curriculum.
A good pathologist can be a gastroenterologist’s best friend. A good GI pathologist, that is.
“Christina Lindenmeyer, MD
Gastroenterology and Hepatology Fellow at Cleveland Clinic, OH; Member of the AASLD Membership and Mentorship Committee, Social Media and Technology Committee and Young Investigator Task Force”
By 2030, pancreatic cancer is projected to be the second-leading cause of cancer death, according to an estimate by SSAT and the Americas Hepato-Pancreato-Biliary Association (AHPBA).
During Sunday’s ASGE Clinical Symposium ERCP: Staying Out of Trouble Situations, four experts will offer practical advice for overcoming common challenges when performing endoscopic retrograde cholangiopancreatography (ERCP).
A panel of experts will discuss the evolving science and best practices for treating motility disorders on Sunday during the annual Josephine and Michael Camilleri, MD, Lecture — Motility Matters 2017: An Interactive Forum to Debate What Progress the Field Has Made in the Treatment of GI Motility Disorders.
At a time when the health care community is facing challenges that range from increasing administrative burdens to decreasing autonomy to reimbursement changes, many physicians are experiencing a decreased sense of purpose, leading to burnout.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) created the Drug-Induced Liver Injury (DILI) Network to collect and analyze cases of severe liver injury caused by prescription drugs, herbal products and supplements.
